4-氨基水杨酸 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "4-氨基水杨酸" in Chinese language version.

refsWebsite

Global rank Chinese rank

18nih.gov

4^th place

5^th place

15doi.org

2^nd place

23^rd place

8web.archive.org

1^st place

4archive.org

6^th place

4^th place

2drugs.com

399^th place

208^th place

2handle.net

102^nd place

492^nd place

2semanticscholar.org

11^th place

332^nd place

1europa.eu

68^th place

209^th place

1iges.or.jp

low place

1rxlist.com

7,927^th place

5,088^th place

1fda.gov

447^th place

581^st place

1chemspider.com

8,573^rd place

6,874^th place

archive.org

World Health Organization. Stuart MC, Kouimtzi M, Hill SR , 编. WHO Model Formulary 2008. World Health Organization. 2009: 140. ISBN 9789241547659. hdl:10665/44053 .
Jiang YM, Mo XA, Du FQ, Fu X, Zhu XY, Gao HY, et al. Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study. Journal of Occupational and Environmental Medicine. June 2006, 48 (6): 644–649. PMC 4180660 . PMID 16766929. doi:10.1097/01.jom.0000204114.01893.3e.
Boman G. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. European Journal of Clinical Pharmacology. 1974, 7 (3): 217–225. PMID 4854257. S2CID 24202603. doi:10.1007/BF00560384.
Vetuschi C, Ragno G, Mazzeo P. Determination of p-aminosalicylic acid and m-aminophenol by derivative UV-spectrophotometry. Journal of Pharmaceutical and Biomedical Analysis. 1988, 6 (4): 383–391. PMID 16867404. doi:10.1016/0731-7085(88)80003-7.

chemspider.com

Aminosalicylic Acid. ChemSpider. [2024-04-29]. （原始内容存档于2023-11-03）.

doi.org

Donald PR, Diacon AH. Para-aminosalicylic acid: the return of an old friend. The Lancet. Infectious Diseases. September 2015, 15 (9): 1091–1099. PMID 26277036. doi:10.1016/s1473-3099(15)00263-7.
Smith NP, Ryan TJ, Sanderson KV, Sarkany I. Lichen scrofulosorum. A report of four cases. The British Journal of Dermatology. March 1976, 94 (3): 319–325. PMID 1252363. S2CID 26281951. doi:10.1111/j.1365-2133.1976.tb04391.x.
Black JM, Sutherland IB. Two Incidents of Tuberculous Infection by Milk from Attested Herds. British Medical Journal. June 1961, 1 (5241): 1732–1735. PMC 1954350 . PMID 20789163. doi:10.1136/bmj.1.5241.1732.
Daniel F, Seksik P, Cacheux W, Jian R, Marteau P. Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis. Inflammatory Bowel Diseases. May 2004, 10 (3): 258–260. PMID 15290921. doi:10.1097/00054725-200405000-00013.
Jiang YM, Mo XA, Du FQ, Fu X, Zhu XY, Gao HY, et al. Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study. Journal of Occupational and Environmental Medicine. June 2006, 48 (6): 644–649. PMC 4180660 . PMID 16766929. doi:10.1097/01.jom.0000204114.01893.3e.
Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. The New England Journal of Medicine. September 1973, 289 (10): 491–495. PMID 4146729. doi:10.1056/NEJM197309062891001.
Szeinberg A, Sheba C, Hirshorn N, Bodonyi E. Studies on erthrocytes in cases with past history of favism and drug-induced acute hemolytic anemia. Blood. July 1957, 12 (7): 603–613. PMID 13436516. doi:10.1182/blood.V12.7.603.603 .
Macgregor AG, Somner AR. The anti-thyroid action of para-aminosalicylic acid. Lancet. November 1954, 267 (6845): 931–936. PMID 13213079. doi:10.1016/S0140-6736(54)92552-0.
Boman G. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. European Journal of Clinical Pharmacology. 1974, 7 (3): 217–225. PMID 4854257. S2CID 24202603. doi:10.1007/BF00560384.
Vetuschi C, Ragno G, Mazzeo P. Determination of p-aminosalicylic acid and m-aminophenol by derivative UV-spectrophotometry. Journal of Pharmaceutical and Biomedical Analysis. 1988, 6 (4): 383–391. PMID 16867404. doi:10.1016/0731-7085(88)80003-7.
Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, et al. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. The Journal of Biological Chemistry. August 2013, 288 (32): 23447–23456. PMC 3789992 . PMID 23779105. doi:10.1074/jbc.m113.475798 .
Minato Y, Thiede JM, Kordus SL, McKlveen EJ, Turman BJ, Baughn AD. Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance. Antimicrobial Agents and Chemotherapy. September 2015, 59 (9): 5097–5106. PMC 4538520 . PMID 26033719. doi:10.1128/AAC.00647-15.
Zhao F, Wang XD, Erber LN, Luo M, Guo AZ, Yang SS, et al. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2014-01-01, 58 (3): 1479–1487. PMC 3957869 . PMID 24366731. doi:10.1128/aac.01775-13.
Lehmann J. The treatment of tuberculosis in Sweden with para-aminosalicylic acid; a review. Diseases of the Chest. December 1949, 16 (6): 684–703, illust. PMID 15396516. doi:10.1378/chest.16.6.684.
Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet. January 1946, 1 (6384): 15–16. PMID 21008766. doi:10.1016/s0140-6736(46)91185-3.

drugs.com

Aminosalicylic acid (Paser) Use During Pregnancy. Drugs.com. 2020-02-28 [2020-04-03]. （原始内容存档于2020-09-15）.
Aminosalicylic Acid. The American Society of Health-System Pharmacists. [8 December 2016]. （原始内容存档于2016-12-20）.

europa.eu

ema.europa.eu

Granupas (previously Para-aminosalicylic acid Lucane). European Medicines Agency (EMA). 17 September 2018 -09-17 [2020-04-03]. （原始内容存档于2020-08-15）. 请检查|date=中的日期值 (帮助)

fda.gov

accessdata.fda.gov

Paser: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2020-04-03]. （原始内容存档于2020-09-15）.

handle.net

hdl.handle.net

World Health Organization. Stuart MC, Kouimtzi M, Hill SR , 编. WHO Model Formulary 2008. World Health Organization. 2009: 140. ISBN 9789241547659. hdl:10665/44053 .
World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

iges.or.jp

ipcc-nggip.iges.or.jp

Ramanathan, Meenakshi R.; Sanders, James M. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions (PDF). [2024-05-04]. （原始内容存档 (PDF)于2023-11-09）. PAS has demonstrated to be bacteriostatic against TB and is therefore listed in major guidelines only as combination therapy for MDR-TB [56S,57S,88S].

nih.gov

ncbi.nlm.nih.gov

Donald PR, Diacon AH. Para-aminosalicylic acid: the return of an old friend. The Lancet. Infectious Diseases. September 2015, 15 (9): 1091–1099. PMID 26277036. doi:10.1016/s1473-3099(15)00263-7.
Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. The International Journal of Tuberculosis and Lung Disease. September 2000, 4 (9): 796–806. PMID 10985648.
Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. The International Journal of Tuberculosis and Lung Disease. October 1999, 3 (10 Suppl 2): S231–S279. PMID 10529902.
Smith NP, Ryan TJ, Sanderson KV, Sarkany I. Lichen scrofulosorum. A report of four cases. The British Journal of Dermatology. March 1976, 94 (3): 319–325. PMID 1252363. S2CID 26281951. doi:10.1111/j.1365-2133.1976.tb04391.x.
Black JM, Sutherland IB. Two Incidents of Tuberculous Infection by Milk from Attested Herds. British Medical Journal. June 1961, 1 (5241): 1732–1735. PMC 1954350 . PMID 20789163. doi:10.1136/bmj.1.5241.1732.
Daniel F, Seksik P, Cacheux W, Jian R, Marteau P. Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis. Inflammatory Bowel Diseases. May 2004, 10 (3): 258–260. PMID 15290921. doi:10.1097/00054725-200405000-00013.
Jiang YM, Mo XA, Du FQ, Fu X, Zhu XY, Gao HY, et al. Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study. Journal of Occupational and Environmental Medicine. June 2006, 48 (6): 644–649. PMC 4180660 . PMID 16766929. doi:10.1097/01.jom.0000204114.01893.3e.
Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. The New England Journal of Medicine. September 1973, 289 (10): 491–495. PMID 4146729. doi:10.1056/NEJM197309062891001.
Szeinberg A, Sheba C, Hirshorn N, Bodonyi E. Studies on erthrocytes in cases with past history of favism and drug-induced acute hemolytic anemia. Blood. July 1957, 12 (7): 603–613. PMID 13436516. doi:10.1182/blood.V12.7.603.603 .
Macgregor AG, Somner AR. The anti-thyroid action of para-aminosalicylic acid. Lancet. November 1954, 267 (6845): 931–936. PMID 13213079. doi:10.1016/S0140-6736(54)92552-0.
Boman G. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. European Journal of Clinical Pharmacology. 1974, 7 (3): 217–225. PMID 4854257. S2CID 24202603. doi:10.1007/BF00560384.
Vetuschi C, Ragno G, Mazzeo P. Determination of p-aminosalicylic acid and m-aminophenol by derivative UV-spectrophotometry. Journal of Pharmaceutical and Biomedical Analysis. 1988, 6 (4): 383–391. PMID 16867404. doi:10.1016/0731-7085(88)80003-7.
Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, et al. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. The Journal of Biological Chemistry. August 2013, 288 (32): 23447–23456. PMC 3789992 . PMID 23779105. doi:10.1074/jbc.m113.475798 .
Minato Y, Thiede JM, Kordus SL, McKlveen EJ, Turman BJ, Baughn AD. Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance. Antimicrobial Agents and Chemotherapy. September 2015, 59 (9): 5097–5106. PMC 4538520 . PMID 26033719. doi:10.1128/AAC.00647-15.
Zhao F, Wang XD, Erber LN, Luo M, Guo AZ, Yang SS, et al. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2014-01-01, 58 (3): 1479–1487. PMC 3957869 . PMID 24366731. doi:10.1128/aac.01775-13.
Lehmann J. The treatment of tuberculosis in Sweden with para-aminosalicylic acid; a review. Diseases of the Chest. December 1949, 16 (6): 684–703, illust. PMID 15396516. doi:10.1378/chest.16.6.684.
Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet. January 1946, 1 (6384): 15–16. PMID 21008766. doi:10.1016/s0140-6736(46)91185-3.

dailymed.nlm.nih.gov

Paser- aminosalicylic acid granule, delayed release. DailyMed. 1 May 2010 [2020-04-03]. （原始内容存档于2020-08-03）.

rxlist.com

Paser. RxList. [2008-10-10]. （原始内容存档于2008-09-13）.

semanticscholar.org

api.semanticscholar.org

Smith NP, Ryan TJ, Sanderson KV, Sarkany I. Lichen scrofulosorum. A report of four cases. The British Journal of Dermatology. March 1976, 94 (3): 319–325. PMID 1252363. S2CID 26281951. doi:10.1111/j.1365-2133.1976.tb04391.x.
Boman G. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. European Journal of Clinical Pharmacology. 1974, 7 (3): 217–225. PMID 4854257. S2CID 24202603. doi:10.1007/BF00560384.

web.archive.org

Aminosalicylic acid (Paser) Use During Pregnancy. Drugs.com. 2020-02-28 [2020-04-03]. （原始内容存档于2020-09-15）.
Aminosalicylic Acid. The American Society of Health-System Pharmacists. [8 December 2016]. （原始内容存档于2016-12-20）.
Granupas (previously Para-aminosalicylic acid Lucane). European Medicines Agency (EMA). 17 September 2018 -09-17 [2020-04-03]. （原始内容存档于2020-08-15）. 请检查|date=中的日期值 (帮助)
Paser- aminosalicylic acid granule, delayed release. DailyMed. 1 May 2010 [2020-04-03]. （原始内容存档于2020-08-03）.
Ramanathan, Meenakshi R.; Sanders, James M. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions (PDF). [2024-05-04]. （原始内容存档 (PDF)于2023-11-09）. PAS has demonstrated to be bacteriostatic against TB and is therefore listed in major guidelines only as combination therapy for MDR-TB [56S,57S,88S].
Paser. RxList. [2008-10-10]. （原始内容存档于2008-09-13）.
Paser: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2020-04-03]. （原始内容存档于2020-09-15）.
Aminosalicylic Acid. ChemSpider. [2024-04-29]. （原始内容存档于2023-11-03）.